Option chain shows key data for Telix Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Telix Pharmaceuticals.

Telix Pharmaceuticals (NASDAQ:TLX) Stock, Option Chain

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Telix Pharmaceuticals

Recent Gains

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BRDG

DGNX

FRPT

GOOS

ZETA

Bridge Investment Group, Telix Pharmaceuticals, Sun Communities, And Other Big Stocks Moving Higher On Monday

SLB Flickr

Intraday Update

BZAI

CNCK

COKE

INTC

LAES

QRVO

SMLR

SLB Posts Upbeat Results, Joins Bank OZK, Qorvo And Other Big Stocks Moving Higher On Friday

Trans-Lux Not Successful in NYSE AMEX Delisting Appeal 

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals Ltd

NEW MURCHISON GOLD LTD by NEW MURCHISON GOLD LTD

New Murchison Gold Ltd

Press Releases

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform

Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans

Health Care

General

Illuccix® Approved in the United Kingdom

Telix to Showcase Urology Pipeline at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2025)

Earnings

Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion

Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami

FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

Telix Adds Lead-212 Isotope Production Capability

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

RDGL

Arcellx

ADMA Biologics

Alkermes

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Nuvalent

Vaxcyte

PTC Therapeutics

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

TG Therapeutics

Zai Lab Limited - American Depositary Shares

Comments

Telix Pharmaceuticals

Telix Pharmaceuticals (TLX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga